## Abstract Tamoxifen has contributed to a dramatic reduction in breast cancer mortality and recent results indicate that aromatase inhibitors may further improve survival in some patients. Nevertheless, a substantial proportion of patients become resistant to treatment. To date, with the exception
A demonstration of androgen and estrogen receptors in a human breast cancer using a new protamine sulfate assay
β Scribed by Marc Lippman; Karen Huff
- Publisher
- John Wiley and Sons
- Year
- 1976
- Tongue
- English
- Weight
- 514 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Separate receptors for estrogen and androgen are demonstrated in cells from metastic human breast cancer. By criteria of binding affinity, number of binding sites, and specificity of the receptor for different steroids, the receptors are shown to be distinguishable. The protamine sulfate receptor assay technique employed allows both kinds of receptor to be quantified conveniently and reproducibly without interference by plasma steroid-binding components.
π SIMILAR VOLUMES
A detailed histopathologic analysis of 399 primary breast carcinomas was performed, and several morphologic features were correlated with the estrogen receptor (ER) status. In all cases ER status was determined immunocytochemically by estrogen receptor immunocytochemical assay (ER-ICA). In 359 carci
A displacement assay with tamoxifen, based on the relative binding affinity of tamoxifen and estradiol for the estrogen receptor (ER), was proposed in 1990 as prognostic indicator for breast-cancer patients. Validation of its predictive results in relation to the outcome of 73 patients with ER Ψ tum